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Human severe sepsis cytokine mixture increases
β2-integrin-dependent polymorphonuclear
leukocyte adhesion to cerebral microvascular
endothelial cells in vitro
Chris Blom1, Brittany L Deller1, Douglas D Fraser1,2,3,4,5, Eric K Patterson3, Claudio M Martin3,6, Bryan Young5,
Patricia C Liaw7,8, Payam Yazdan-Ashoori1, Angelica Ortiz2, Brian Webb9, Greg Kilmer9, David E Carter10
and Gediminas Cepinskas3,11*
Abstract
Introduction: Sepsis-associated encephalopathy (SAE) is a state of acute brain dysfunction in response to a
systemic infection. We propose that systemic inflammation during sepsis causes increased adhesion of leukocytes
to the brain microvasculature, resulting in blood-brain barrier dysfunction. Thus, our objectives were to measure
inflammatory analytes in plasma of severe sepsis patients to create an experimental cytokine mixture (CM), and to
use this CM to investigate the activation and interactions of polymorphonuclear leukocytes (PMN) and human
cerebrovascular endothelial cells (hCMEC/D3) in vitro.
Methods: The concentrations of 41 inflammatory analytes were quantified in plasma obtained from 20 severe
sepsis patients and 20 age- and sex-matched healthy controls employing an antibody microarray. Two CMs were
prepared to mimic severe sepsis (SSCM) and control (CCM), and these CMs were then used for PMN and hCMEC/D3
stimulation in vitro. PMN adhesion to hCMEC/D3 was assessed under conditions of flow (shear stress 0.7 dyn/cm2).
Results: Eight inflammatory analytes elevated in plasma obtained from severe sepsis patients were used to prepare
SSCM and CCM. Stimulation of PMN with SSCM led to a marked increase in PMN adhesion to hCMEC/D3, as compared
to CCM. PMN adhesion was abolished with neutralizing antibodies to either β2 (CD18), αL/β2 (CD11α/CD18; LFA-1) or
αM/β2 (CD11β/CD18; Mac-1) integrins. In addition, immune-neutralization of the endothelial (hCMEC/D3) cell adhesion
molecule, ICAM-1 (CD54) also suppressed PMN adhesion.
Conclusions: Human SSCM up-regulates PMN pro-adhesive phenotype and promotes PMN adhesion to cerebrovascular
endothelial cells through a β2-integrin-ICAM-1-dependent mechanism. PMN adhesion to the brain microvasculature
may contribute to SAE.
Introduction
Sepsis, a systemic inflammatory response to a known or sus-
pected infection, is a leading cause of admission and mortal-
ity in intensive care units (ICUs) [1]. Severe sepsis refers to
sepsis accompanied by acute organ dysfunction [2]. Up to
70% of patients with severe sepsis experience an acute
neurological dysfunction known as sepsis-associated en-
cephalopathy (SAE) [3]. Acute brain dysfunction in severe
sepsis patients is associated with increased rates of mortal-
ity and long-term cognitive impairment in survivors [4,5].
The mechanisms of SAE are unknown, but possible
instigating factors may be the early activation of the in-
nate immune response and microcirculatory dysfunction
that are common manifestations of severe sepsis [6,7].
Activated leukocytes and vascular endothelial cells
contribute to systemically increased concentrations of
cytokines and chemokines in patients with sepsis [8].
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Circulating inflammatory mediator(s) activate polymorpho-
nuclear leukocytes (PMN), leading to up-regulation of the
pro-adhesive phenotype and recruitment of PMN to the
inflamed tissues and/or organs [9,10]. While PMN are
critical for the host defense against pathogens, the sys-
temic activation of PMN also correlates with organ dys-
function in septic patients [11]. Animal models of sepsis
demonstrate that overwhelming PMN recruitment is asso-
ciated with dysfunction of the affected organs, including
the brain [12-14].
Leukocyte (such as PMN) recruitment to the micro-
vasculature can be broken down to two general steps:
rolling and adhesion [9,15]. Interactions between adhe-
sion molecules expressed constitutively or in response to
inflammation, by both endothelial cells and leukocytes,
are responsible for cellular interactions. PMN rolling is
primarily controlled by a family of glycoproteins (selec-
tins) expressed on both PMN (L-selectin) and endothe-
lial cells (such as P- and E-selectins). Subsequently,
PMN firm adhesion is mediated primarily through β-2
integrin (CD18; expressed by PMN) and ICAM-1 (CD54;
expressed by endothelial cells) interaction. The β2-
integrins form heterodimers with either integrin-αL
(CD11a) or integrin-αM (CD11b) to form αL/β2 (CD11a/
CD18; LFA-1) or αM/β2 (CD11b/CD18; Mac-1), respect-
ively. Both LFA-1 and Mac-1 interact with ICAM-1 to
promote PMN adhesion to endothelial cells.
Endothelial cells of the blood-brain barrier (BBB) are
likely disrupted during SAE, as vasogenic edema is con-
sistently found on head magnetic resonance imaging in
sepsis [16]. Lesions in the subcortical white matter, also
consistent with vasogenic edema, are particularly prom-
inent in cases of fatal septic shock [17]. Increased signal
associated with contrast agent administration during SAE
indicates BBB disruption [6]. The mechanism(s) of BBB
disruption in sepsis, however, remain poorly understood.
In this study, we hypothesized that the inflammation
associated with severe sepsis would result in greater
PMN interactions with the brain microvasculature. Thus,
we first aimed to measure circulating inflammatory medi-
ators in blood plasma from patients with severe sepsis,
and then investigate the effects of these inflammatory
analytes on the pro-adhesive phenotype of human PMNs
and human cerebrovascular endothelial cells (hCMEC/D3)
in vitro.
Materials and methods
The institutional review boards of Hamilton Health
Sciences (Hamilton, ON, Canada) and the University of
Western Ontario (London, ON, Canada) approved this
study. Consent was obtained from the ICU patients or
their legal guardians. Consistency of patient blood sam-
pling in the participating centers was monitored by a
study investigator (PCL).
Severe sepsis patients and blood plasma
Blood plasma collection was described previously [18].
Briefly, blood was collected from ICU patients within the
first 24 hours of severe sepsis diagnosis according to the
American College of Chest Physicians/Society of Critical
Care Medicine (ACCP/SCCM) guidelines [2,19]. Venous
blood (4.5 mL) was drawn via indwelling catheters (severe
sepsis patients) or fresh venipuncture (from age- and
sex-matched healthy controls), and immediately trans-
ferred into 15 mL polypropylene tubes (VWR, Mississauga,
ON, Canada) containing 0.5 mL of 0.105 mol/L buffered
trisodium citrate (pH 5.4) (Sigma-Aldrich, St. Louis, MO,
USA) with 100 μL of 1 mol/L benzamidine HCl (approxi-
mately 20 mmol/L benzamidine), a serine protease in-
hibitor (Sigma-Aldrich, St. Louis, MO, USA). The blood
was immediately centrifuged at 1,500 g for 10 minutes at
20°C, and the plasma was stored in aliquots at −80°C.
Care was taken to ensure that freeze/thaw cycles were
avoided. Baseline characteristics of severe sepsis patients
were recorded at ICU admission (Table 1). Baseline
Table 1 Baseline characteristics of 20 patients with severe
sepsis on ICU day 1
Age, years 59 ± 4 (20-80)
Gender, female 6 (30%)
APACHE II score 25.8 ± 2.1 (6-42)
MOD score 10.4 ± 0.86 (3-15)
Absolute neutrophil count (ANC)a 11.5 ± 0.9 (3.7-19.5)
Co-morbidities, number (% of total)
Cardiovascular 9 (45%)
Pulmonary 5 (25%)
Hepatitis/pancreatitis 5 (25%)
Inflammatory 3 (15%)
Neurological 3 (15%)
Renal 3 (15%)
Diabetes 2 (10%)
Primary site of infection, number (% of total)
Lung 11 (55%)
Abdomen 3 (15%)
Blood 1 (5%)
Urinary Tract 0 (0%)
Other 4 (20%)
Unknown 1 (5%)
Total number of positive cultures (% of total)b
Gram-negative bacteria 10 (50%)
Gram-positive bacteria 9 (45%)
Fungus 2 (10%)
Data are presented as mean ± SE (range) or n (%). aNormal ANC = 1.5-8.0. bIncludes
blood and non-blood cultures, therefore the total is >100%. Four poly-microbial
non-blood cultures were not included in the table. APACHE II, Acute Physiology
and Chronic Health Evaluation II; MOD, Multiple organ dysfunction.
Blom et al. Critical Care  (2015) 19:149 Page 2 of 11
characteristics included demographics, clinical predictive
scores (Acute Physiology and Chronic Health Evaluation
II (APACHE II) and multiple organ dysfunction syndrome
(MODS)), site of infection, positive blood cultures, and
co-morbidities.
Antibody microarray
Sample analysis was performed by an investigator blinded
to the experimental cohort (severe sepsis versus healthy
control) in one laboratory (DDF) as batched samples
[18]. A total of 4 antibody microarrays were used to
analyze the concentrations of 41 different inflamma-
tory mediators in 20 plasma samples from both severe
sepsis patients and age- and sex-matched healthy con-
trols. Plasma samples were each diluted 1:3 in Array
Sample Diluent and were run on a Thermo Scientific
ExcelArray™ (Rockford, IL, USA): Inflammation I (product
number 82002), Inflammation II (product number: 82003),
Chemotaxis (product number: 82006), and Angiogenesis
(product number: 82004) [20].
Protein concentrations were determined for the following
human analytes: angiogenin, basic fibroblast growth factor
(FGFβ), cysteine-cysteine chemokine ligand 1 (CCL1;
I-309), eotaxin, epidermal growth factor (EGF), fas ligand
(FasL), granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor (GM-
CSF), growth-regulated oncogene alpha (GRO-α), heparin-
binding epidermal growth factor (HB-EGF), hepatocyte
growth factor (HGF), interferon gamma (IFNγ), interferon-
inducible protein 10 kDa (IP-10), interleukin-1 alpha
(IL-1α), interleukin-1 beta (IL-1β), interleukin-2 (IL-2),
interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5
(IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-
8 (IL-8), interleukin-10 (IL-10), interleukin-12 (IL-12),
interleukin-13 (IL-13), interleukin-15 (IL-15), interleukin-
17 (IL-17), keratinocyte growth factor (KGF), macrophage-
derived chemokine (MDC), macrophage inflammatory
protein-1 alpha (MIP-1α), macrophage inflammatory
protein-1 beta (MIP-1β), monocyte chemotactic protein-1
(MCP-1), monocyte chemotactic protein-3 (MCP-3),
neutrophil-activating protein-2 (NAP-2), normal T-cell
expressed and secreted (TARC), placenta growth factor
(P1GF), regulated upon activation, normal T cell expressed
and secreted (RANTES), tissue inhibitor of metalloprotein-
ase 1 (TIMP-1), tumor necrosis factor alpha (TNF-α),
tumor necrosis factor beta (TNF-β), and vascular endothe-
lial growth factor (VEGF).
Briefly, 100 μL of multiplexed standards (1,000-12.3
pg/mL) or diluted plasma was applied to each well and
incubated at room temperature on a shaker at 200 rpm
for two hours. After sample incubation, the microarrays
were rinsed three times with wash buffer. Prior to re-
incubation on a shaker for one hour, 75 μL pre-titered
biotinylated detector antibodies were added to each well.
Microarrays were washed three times and 100 μL
Streptavidin DyLight 649 (part of Thermo Scientific
ExcelArray™kit; Thermo Fisher Scientific, Rockford, IL,
USA) was applied to each well, preceding a final incu-
bation of 30 minutes on a shaker. Microarrays were
washed five times and dipped briefly in a final rinse so-
lution. Slides were then centrifuged at approximately 200
g until dry. Methodologies for microarray production and
antibody cross reactivity assays have been described previ-
ously [20]. Cross reactivity on the microarray antibody
pairs is ≤5%, as reported by the manufacturer. Microarrays
were imaged using an Alphascan™ Microarray Imager
(Alpha Innotech, San Leandro, CA, USA) and spot densi-
tometry was performed by Thermo Fisher (Rockford, IL,
USA) using ArrayVision™ Software (GE Healthcare,
Piscataway, NJ, USA).
Human cytokine mixtures
The most up-regulated (P <0.001) human analytes detected
in the plasma of severe sepsis patients (IL-8, G-CSF, IP-10,
GRO-α, HGF, MIP-1β, and MCP-1; Table 2) were selected
to make the severe sepsis cytokine mixture (SSCM) and
control cytokine mixture (CCM). The sepsis-relevant cyto-
kine IL-6 [21,22] was also significantly up-regulated in the
plasma of severe sepsis patients (P = 0.017) and was added
to each cytokine mixture. Recombinant proteins were sus-
pended in PBS containing 1% BSA at 100X concentration
measured in severe sepsis blood plasma or healthy control
blood plasma (Table 2). Each cytokine mixture was stored
at −20°C until thawed for experiments. To treat cells, each
cytokine mixture was diluted at 100X concentration in ei-
ther PBS or VascuLife® EnGS-Mv (LifeLine cell technology,
Walkersville, MD, USA) cell culture medium to the corre-
sponding analyte concentrations measured in control blood
Table 2 Plasma concentration of inflammatory analytes
used to make the control and severe sepsis cytokine
mixtures
Analyte Control Severe sepsis Fold increase P value
MCP-1 41.8 ± 12.1 1067.8 ± 196.4 25 <0.001
G-CSF 29.3 ± 9.5 938.4 ± 278.5 32 <0.001
IL-8 10.0 ± 0.0 211.9 ± 43.4 21 <0.001
HGF 290.3 ± 60.8 3346.8 ± 570.5 12 <0.001
MIP-1β 49.7 ± 12.1 381.1 ± 116.0 8 <0.001
IP-10 214.4 ± 26.8 1552.0 ± 254.5 7 <0.001
GROα 92.5 ± 24.2 637.5 ± 136.3 7 <0.001
IL-6 80.8 ± 31.8 387.6 ± 158.4 5 0.017
Plasma was obtained from severe sepsis patients and compared to plasma from
age- and sex-matched healthy controls. Analytes were measured with antibody
microarray and presented as mean ± SE. Values are in ng/mL (n = 20 per group).
MCP-1-monocyte chemotactic protein-1; GCSF-granulocyte colony-stimulating
factor; IL-8- interleukin-8; HGF- hepatocyte growth factor; MIP-1β- macrophage
inflammatory protein-1 beta; IP-10- interferon-inducible protein 10 kDa;
GRO-α- growth-regulated oncogene alpha; IL-6- interleukin-6.
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plasma or severe sepsis blood plasma, respectively. All hu-
man recombinant analytes were obtained from either
Ebioscience (San Diego, CA, USA) or Invitrogen (Carlsbad,
CA, USA).
Human cerebral microvascular endothelial cells
hCMECs (hCMEC/D3 cell line) were isolated and immor-
talized by Dr Pierre-Olivier Couraud and his colleagues
(INSERM, Paris, France; [23]). The immortalization of
CMEC was performed via sequential lentiviral transduc-
tion of hTERT and SV40 large T antigen transduction into
a primary culture of adult CMEC. The hCMEC/D3 cell
line offers a unique opportunity to study human cerebro-
vascular cells in isolation from other cells, and represents
a stable, fully characterized, and well-differentiated line of
CMEC.
hCMEC/D3 were grown at 37°C and 5% CO2 in VascuLife
EnGS-Mv (LifeLine Cell Technology, Walkersville, MD,
USA) cell culture medium supplemented with recombinant
human EGF (0.2%), EnGS (5 ng/mL), heparin (0.75 U/mL),
fetal bovine serum ((FBS) 5%), ascorbic acid (50 μg/mL),
L-glutamine (10 mM), and hydrocortisone (1.0 μg/mL)
(LifeLine Cell Technology, Walkersville, MD, USA) [24].
Penicillin (100 IU/mL) and streptomycin (100 μg/mL)
(Wisent Inc, St Bruno, QC, Canada) were also added to
cell culture media. hCMEC/D3 at passage 35-50 were
used in all experiments.
Human polymorphonuclear leukocyte isolation
Human PMN were isolated from venous blood of
healthy adults immediately before experiments as previ-
ously described by us [24]. Briefly, heparinized whole
blood (10 mL; 10 U/mL; Pharmaceutical Partners of
Canada, Richmond Hill, ON, Canada) was gently mixed
by inversion (10 times) with 5 mL of 3% dextran in PBS
(pH 7.4). Sedimentation of red blood cells was per-
formed via incubation of the mixture for 20 minutes at
23°C. Blood plasma was removed and gently added onto
5 mL of Histopaque® lymphocyte separation medium
(density of 1.077 g/mL; Sigma-Aldrich, St Louis, MO,
USA). Samples were centrifuged for 30 minutes at 400 × g
at 23°C. Following centrifugation, the pellet (PMN and
remaining red blood cells) was re-suspended in 15 mL cold
red blood cell lysis buffer, containing NH4Cl (8.3 g/L),
KHCO3 (1.0 g/L), and EDTA (0.14 mM) (all purchased
from Sigma-Aldrich, St. Louis, MO, USA) in water, ad-
justed to a pH of 7.2. After five minutes incubation at 4°C,
mixtures were centrifuged at 300 × g for five minutes.
PMN were re-suspended in 1 mL PBS (4°C), stored on ice
until use, and counted using a hemocytometer (VWR,
Mississauga, ON, Canada). This procedure yields a
PMN population that is 95 to 98% viable (as measured
by trypan blue exclusion) and 98% pure (as measured by
acetic acid-crystal violet staining) (both reagents were pur-
chased from Sigma-Aldrich, St. Louis, MO, USA).
Polymorphonuclear leukocyte adhesion to hCMEC/D3
hCMEC/D3 were grown to confluence in μ-Slide VI0.4
parallel flow channels (ibidi; MOFA Global, Ingersoll,
ON, Canada) and interacted with PMN as previously de-
scribed by us [24,25]. Briefly, hCMEC/D3 were seeded at
a density of 11,000 cells per channel and grown for 5
days, followed by 5 hours of stimulation with either
CCM or SSCM diluted in serum free-VascuLife EnGS-
Mv cell culture medium. The CCM and SSCM treat-
ments did not affect hCMEC/D3 viability as assessed by
ViaCount Flex (Cedarlane, Burlington, ON, Canada)
assay and flow-cytometry approach (data not shown).
Each channel was then perfused (that is, washed) in the
presence of laminar shear stress of 0.7 dyn/cm2 for one
minute with VascuLife EnGS-Mv cell culture medium,
using a Harvard Apparatus 22-syringe pump (Instech,
Plymouth Meeting, PA, USA). Subsequently and continu-
ously, hCMEC/D3 were perfused with freshly isolated
PMN (1 × 106 PMN/mL; suspended in serum free-
VascuLife EnGS-Mv cell culture medium) that have been
stimulated either with CCM or SSCM for 10 minutes.
The experiment was visualized and video recorded
using a Nikon DIAPHOT-300 inverted microscope
(Nikon, Chiyoda-ku, Tokyo, Japan) equipped with a
temperature-controlled chamber (37°C) and Panasonic
WJ-810 video-camera (Panasonic, Kadoma, Osaka, Japan)
connected to an SV-video recorder (Panasonic). For each
experiment, 5 random fields of view (0.1 mm2 each) were
recorded for 30 seconds, starting at 4 minutes after initi-
ation of the PMN perfusion. The recorded PMN-hCMEC/
D3 adhesive interactions were video-analyzed to count the
number of firmly adherent PMN (stationary for at least
five seconds). The average number of adherent PMN was
expressed as PMN/0.1 mm2.
Adhesion molecule immuno-neutralization
PMN (2 × 107/mL) suspended in PBS were stimulated
with CCM or SSCM at 23°C for 10 minutes in a total
volume of 0.2 mL. Subsequently, function neutralizing
monoclonal antibodies (all IgG1κ subclass; BioLegend,
San Diego, CA, USA) directed against either human
β2-integrin (clone TS 1/18; 25 μg/mL), human LFA-1
(clone HI111; 5 μg/mL), or Mac-1 (clone ICRF44; 5 μg/mL),
were added to the PMN suspension for an additional 15 mi-
nutes. An isotype control (IgG1κ; BioLegend, San Diego,
CA, USA) antibody was used in parallel experiments at the
corresponding concentrations. Following treatment, PMN
were immediately added to VascuLife EnGS-Mv cell culture
medium to a final concentration of 1 × 106/mL and perfused
over hCMEC/D3.
Blom et al. Critical Care  (2015) 19:149 Page 4 of 11
In some experiments, hCMEC/D3 grown in laminar
flow micro channels (ibidi GmbH) were stimulated with
either CCM or SSCM and subsequently treated with
function neutralizing anti-human ICAM-1 (CD54; clone
HCD54; 5 μg/mL) or isotype control (both IgG1κ sub-
class; BioLegend, San Diego, CA, USA) antibodies in
VascuLife EnGS-Mv cell culture medium for 30 minutes
at 37°C, preceding PMN perfusion.
RNA isolation, cDNA synthesis and quantitative PCR
hCMEC/D3 were seeded (500,000 per well) on six-well
plates and grown for two days, preceding four hours of
stimulation with either CCM or SSCM. Following
stimulation, hCMEC/D3 were washed three times with
PBS and RNA was extracted with 1 mL TRIzol® reagent
(Life Technologies, Carlsbad, CA, USA), as per the
manufacturer’s protocol except the RNA pellet was
washed three times with 75% ethanol. RNA was re-
suspended in 20 μL of 10 mM Tris, pH 8. The purity
and concentration of RNA was determined using a
Biophotometer (Eppendorf, Hamburg, Germany). One
microgram of RNA per sample was reverse transcribed
using iScript™ Reverse Transcription Supermix (Bio-Rad,
Hercules CA, USA) according to the manufacturer’s
protocol.
Quantitative PCR (qPCR) was performed using Sso
Fast™ Probes Supermix (Bio-Rad, Hercules, CA, USA),
according to the manufacturer’s protocol, using cDNA
at concentrations previously determined to be within
90 to 110% efficiency. Primers were predesigned (Applied
Biosystems, Foster City, CA, USA): 18S (Hs99999901_s1),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
Hs99999905_m1), ICAM-1 (Hs00164932_m1), and VCAM-1
(Hs01003372_m1). Real-time PCR was run using a
C1000™ Touch Thermal Cycler with CFX96™ Real-Time
System (Bio-Rad, Hercules CA, USA). Cycling conditions
included one-time enzyme activation at 95°C for 30 seconds,
followed by 50 cycles of denaturation at 95°C for 5 seconds,
and annealing and extension at 60°C for 15 seconds. Target
gene expression was normalized to GAPDH and 18S and
was expressed relative to gene expression by hCMEC/D3
treated with serum-free VascuLife EnGS-Mv cell cul-
ture media.
Statistical analysis
Data were analyzed using SigmaStat 3.5 (Systat Software
Inc., San Jose, CA, USA). Continuous variables are re-
ported with mean ± SE. Groups were pre-screened for
normality and compared with either a Student’s t test or
Mann-Whitney U test. Multiple groups were analyzed
using one-way analysis of variance (ANOVA) with Tukey’s
post-hoc test. A P <0.05 was considered statistically
significant.
Results
Patient characteristics and plasma inflammatory biomarkers
The baseline characteristics at ICU admission of the 20
severe sepsis patients from whom blood plasma was
collected are presented in Table 1. Of these 20 patients
with severe sepsis, 18 had septic shock (90%) and 4 died
(20%). Antibody microarray analysis of plasma from se-
vere sepsis and control patients indicate that 13 out of
the 41 analytes measured were significantly up-regulated
in severe sepsis. The measured concentrations of eight
analytes were used to create the cytokine mixtures, both
SSCM and CCM (IL-8, G-CSF, IP-10, GRO-α, HGF,
MIP-1β, MCP-1, IL-6; Table 2; n = 20 per group). In
addition, FGFβ (802.3 ± 402.9 versus 1,573.4 ± 456.9 ng/
mL; P <0.012), IL-15 (38.6 ± 23.1 versus 256.1 ± 128.7 ng/
mL; P <0.031), MCP-3 (22.4 ± 4.6 versus 93.9 ± 33.0 ng/mL;
P <0.011), HB-EGF (21.2 ± 7.8 versus 642.0 ± 254.4 ng/mL;
P <0.044), and KGF (33.7 ± 9.8 versus 177.1 ± 103.0 ng/mL;
P <0.046) were also significantly up-regulated in the plasma
of severe sepsis patients, but not included in the cytokine
mixtures.
Polymorphonuclear leukocyte adhesion to hCMEC/D3
PMN and/or hCMEC/D3 were stimulated with either
SSCM or CCM and assessed for PMN adhesion to
hCMEC/D3 in the presence of flow (laminar shear stress
0.7 dyn/cm2). Stimulation of hCMEC/D3 with SSCM
did not significantly increase the adhesion of naïve
(unstimulated) PMN (Figure 1). On the contrary, stimu-
lation of PMN with SSCM significantly increased PMN
adhesion to hCMEC/D3 (P <0.05; n = 7; Figure 1), while
simultaneous treatment of PMN and hCMEC/D3 with
SSCM (co-stimulation) had no additive effects.
Role of β2-integrins and ICAM-1 in polymorphonuclear
leukocyte adhesion to hCMEC/D3
Antibody neutralization was used to assess the role of
β2-integrins on SSCM-induced PMN adhesion to
hCMEC/D3. SSCM-stimulated PMN were treated with
either a function neutralizing anti-β2-integrin antibody
or isotype control antibody before hCMEC/D3 interaction.
Anti-β2-integrin antibody, but not isotype matching control
antibody, prevented PMN adhesion to naïve (unstimulated)
hCMEC/D3 (P <0.05; n = 4; Figure 2A). The anti-β2-integrin
antibody was also effective in preventing SSCM-induced
PMN adhesion to SSCM-stimulated hCMEC/D3 (P <0.05;
n = 4; Figure 2B). Finally, neutralizing antibodies re-
vealed that both αL/β2 (CD11a/CD18; LFA-1) and αM/β2
(CD11b/CD18; Mac-1) integrins equally contribute to
SSCM-induced PMN adhesion to hCMEC/D3 (P <0.05;
n = 4; Figure 3).
Interfering with hCMEC/D3 ICAM-1 function by pre-
treatment of hCMEC/D3 with an anti-ICAM-1 neutral-
izing antibody was also effective in reducing adhesion of
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SSCM-stimulated PMN to SSCM-stimulated hCMEC/
D3 (P <0.05; n = 6; Figure 4). The reduced PMN adhe-
sion to hCMEC/D3 following immune-neutralization of
ICAM-1 was likely due to interference with the consti-
tutively expressed levels of ICAM-1 on the surface of
hCMEC/D3, as SSCM failed to up-regulate ICAM-1 ex-
pression as assessed by qPCR (Figure 5).
Discussion
The present study identified an inflammatory profile in
severe sepsis patients at ICU day one that up-regulated a
pro-adhesive phenotype of PMN, resulting in increased
adhesion to hCMEC/D3 in vitro. These effects may be
important for the pathophysiology of SAE, as adhered
and/or activated PMN could result in dysfunction of
the BBB.
The extracellular environment of the brain is highly
regulated by the BBB. Dysfunction of the BBB has been
demonstrated with brain imaging in patients with SAE
[6,16,17], and BBB dysfunction is also observed in
lipopolysaccharide-challenged animals [26]. Injury to the
cellular components of the BBB, including cerebrovascu-
lar endothelial cells [27], pericytes [28], and astrocytes
[29], was observed in experimental animal models of
sepsis. Cerebrovascular endothelial cell dysfunction may
lead to dysregulation of the brain extracellular environment
and subsequent neuronal dysfunction, thereby causing
SAE.
In the current study, we collected blood plasma sam-
ples from ICU patients within the first 24 hours of
severe sepsis diagnosis. Encephalopathy occurs early in
sepsis, often developing on the first day of ICU admis-
sion [30]. Thus, blood was sampled at a critical time
point for SAE development.
A total of 13 inflammatory analytes were up-regulated
in blood plasma obtained from severe sepsis patients
compared to blood plasma from age- and sex-matched
healthy controls. Most of the up-regulated analytes are
Figure 2 Effects of anti-β2-integrin (CD18) antibody on severe
sepsis cytokine mixture (SSCM)-induced PMN adhesion to
hCMEC/D3. PMN were first stimulated with CCM or SSCM for 10
minutes and subsequently treated with anti-β2-integrin (CD18) function
neutralizing antibody (or control isotype antibody) for an additional 15
minutes. PMN adhesion to stimulated PMN (A) or stimulated PMN
and hCMEC/D3 (B) was assessed in the presence of flow (laminar shear
stress 0.7 dyn/cm2). n = 4. *P <0.05 as compared to corresponding
control cytokine mixture (CCM); # P <0.05 as compared to isotype
IgG treatment. CCM-control cytokine mixture; SSCM-severe sepsis
cytokine mixture; hCMEC/D3-human cerebral microvascular endothelial
cells/D3; PMN-polymorphonuclear leukocytes; IgG-immunoglobulin G;
CD18-cluster of differentiation 18.
Figure 1 PMN adhesion to hCMEC/D3 following stimulation
with severe sepsis cytokine mixture (SSCM). hCMEC/D3 were
grown on laminar flow microchannels and interacted with PMN
following stimulation of hCMEC/D3, PMN, or both PMN and hCMEC/D3,
with CCM or SSCM. In these experiments, hCMEC/D3 were stimulated
with CCM or SSCM for five hours. PMN were stimulated for 10 minutes
immediately before interacting them with hCMEC/D3. PMN adhesion to
hCMEC/D3 was assessed in the presence of flow (laminar shear stress
0.7 dyn/cm2). n = 7; *P <0.05 as compared to corresponding control
cytokine mixture (CCM). CCM-control cytokine mixture; SSCM-severe
sepsis cytokine mixture; hCMEC/D3-human cerebral microvascular
endothelial cells/D3; PMN-polymorphonuclear leukocytes.
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pro-inflammatory cytokines (such as IL-6) and CXC- and
CC-family chemokines (such as IL-8, GRO-α, MCP-1, and
MIP-1β), with well-documented roles in cellular activation
and leukocyte recruitment to vascular endothelium
[31,32]. In addition, a marked increase in cell growth-
modulating factors (such as HGF, FGFβ, HB-EGF, and
KGF) in the circulation of severe sepsis patients was also
found. The role of these growth factors in tissue remo-
delling has been shown previously, but the exact role of
Figure 4 Effects of anti-ICAM-1 antibody on severe sepsis
cytokine mixture (SSCM)-induced PMN adhesion to hCMEC/D3.
hCMEC/D3 were stimulated with CCM or SSCM for 5 hours, treated
with anti-ICAM-1 function neutralizing antibody for 30 minutes, and
interacted with CCM- or SSCM-stimulated (10 minutes) PMN to
assess PMN adhesion in the presence of flow (laminar shear stress
0.7 dyn/cm2). n = 6; *P <0.05 as compared to corresponding control
cytokine mixture (CCM); # P <0.05 as compared to isotype IgG
treatment. CCM-control cytokine mixture; SSCM-severe sepsis
cytokine mixture; hCMEC/D3-human cerebral microvascular endothelial
cells/D3; PMN-polymorphonuclear leukocytes; Ab-antibody;
ICAM-1 – intercellular adhesion molecule-1.
Figure 5 Effects of severe sepsis cytokine mixture (SSCM) on
adhesion molecule ICAM-1 and VCAM-1 expression in hCMEC/D3.
hCMEC/D3 were stimulated for 4 hours with either CCM or SSCM
preceding analysis of VCAM-1 and ICAM-1 gene expression using
qPCR. Data is presented as gene expression normalized to GAPDH
and 18S expression, relative to hCMEC/D3 treated with serum-free
VascuLife EnGS-Mv cell culture media (n = 5). CCM-control cytokine
mixture; SSCM-severe sepsis cytokine mixture; hCMEC/D3-human
cerebral microvascular endothelial cells/D3; ICAM-1 – intercellular
adhesion molecule-1; VCAM-1 – vascular cell adhesion molecule-1;
18S-18S ribosomal RNA; GAPDH-glyceraldehyde 3-phosphate
dehydrogenase; qPCR- quantitative polymerase chain reaction.
Figure 3 Effects of anti-LFA-1 and anti-Mac-1 antibodies on
severe sepsis cytokine mixture (SSCM)-induced PMN adhesion
to hCMEC/D3. PMN were first stimulated with CCM or SSCM for
10 minutes and subsequently treated with anti-LFA-1 or anti-Mac-1
function neutralizing antibody (or control isotype antibody) for an
additional 15 minutes. PMN adhesion to stimulated PMN (A) or
stimulated PMN and hCMEC/D3 (B) was assessed in the presence of
flow (laminar shear stress 0.7 dyn/cm2). n = 4. *P <0.05 as compared
to corresponding control cytokine mixture (CCM); # P <0.05 as
compared to isotype IgG treatment. CCM-control cytokine mixture;
SSCM-severe sepsis cytokine mixture; hCMEC/D3-human cerebral
microvascular endothelial cells/D3; PMN-polymorphonuclear leukocytes;
IgG-immunoglobulin G; LFA-1 - lymphocyte function-associated antigen
1; Mac-1 - macrophage-1 antigen.
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these molecules in the pathophysiology of severe sepsis is
unknown.
Acute expression of individual cytokines and chemo-
kines (such as IL-6, IL-8, MCP-1, and G-CSF) has been
reported to correlate with the presence and severity of
organ dysfunction in patients with severe sepsis and sep-
tic shock [22]. Interestingly, cytokines that are most
commonly employed in experimental models of inflam-
mation and/or sepsis (TNF-α, IL-1β, and IFN-γ) were not
significantly increased in severe sepsis plasma obtained
within 24 hours of ICU admission. One possible ex-
planation for the latter phenomenon could be that the
cytokines mentioned above may be expressed more prom-
inently at different stages (for example, earlier or later
than 24 hours post-admission time) and severities of sep-
sis, or in subgroups of severe sepsis patients [22,33]. Thus,
it would be plausible to assume that the severe sepsis ana-
lyte profile within the first 24 hours of ICU admission rep-
resents not an ‘early’, but rather a ‘later’ cytokine response,
that may intensify and perpetuate the inflammatory
response.
One unique aspect of this study was the use of SSCM
that consisted of eight cytokines and chemokines at the
actual concentrations detected in the plasma of severe
sepsis patients. In contrast, previous sepsis studies in the
field have used a single cytokine and chemokine-based
stimulation of the cells at often ‘un-physiologically’ high
concentrations. In the current study we employed a
severe sepsis analyte profile obtained at a time-point of
disease that is clinically relevant to SAE development
[3]. Our results indicate that PMN, but not hCMEC/D3, are
more responsive to SSCM, with regards to up-regulation of
the pro-adhesive phenotype. Stimulation of PMN, or PMN
and hCMEC/D3, with SSCM resulted in an increased
adhesion of PMN to hCMEC/D3 under in vitro condi-
tions of flow, whereas stimulation of hCMEC/D3 only
had no effect on PMN adhesion. This latter phenomenon
may be explained by the inability of SSCM to up-regulate
inducible adhesion molecule (such as ICAM-1 or VCAM-1)
expression in hCMEC/D3 (as evidenced by qPCR analysis;
Figure 5). On the other hand, the levels of constitutively
expressed ICAM-1 on the surface of endothelial cells
are sufficient to promote adhesion of activated PMN.
Whether cerebrovascular endothelial cells (such as
hCMEC/D3) are less sensitive to the pro-inflammatory
cytokine and chemokine stimulation at physiologic
concentrations as compared to the non-brain endothe-
lial cells (such as pulmonary microvascular endothelial
cells or umbilical vein endothelial cells) remains to be
determined.
Our data indicate that β2-integrins (such as LFA-1 and
Mac-1) are required for SSCM-induced PMN adhesion
to hCMEC/D3. Interestingly, immune-neutralization of
ICAM-1 (a receptor for β2-integrins) in hCMEC/D3
was also very effective in reducing PMN adhesion, des-
pite the fact that SSCM failed to up-regulate ICAM-1 ex-
pression in hCMEC/D3. The latter may be explained
by reduced availability of the constitutively expressed
ICAM-1 following treatment of hCMEC/D3 with the
immunoneutralizing anti-ICAM-1 antibody.
Up-regulated surface expression of β2-integrin has been
reported on freshly isolated PMN stimulated with blood
plasma obtained from severe sepsis patients 24 hours
after diagnosis [34]. Treatment of PMN with individual
chemokines, such as IL-8, may also induce LFA-1- or
Mac-1-dependent PMN adhesion [35,36]. The up-regulation
of β2-integrins (such as LFA-1 and Mac-1) surface ex-
pression is not always a prerequisite for LFA-1- and
Mac-1-dependent adhesion. Rather, β2-integrins that are
constitutively expressed on the leukocyte cell membrane
undergo conformational activation to a pro-adherent state
that promotes leukocyte adhesion to molecules such as
ICAM-1 [37,38]. LFA-1 and Mac-1 are known to bind
ICAM-1 on vascular endothelial cells to facilitate PMN
adhesion [39,40]. Ameliorated PMN recruitment to
brain tissue has been demonstrated during endotoxe-
mia in ICAM-1-deficient mice, similar to our findings
in which an anti-ICAM-1 antibody reduced PMN ad-
hesion to hCMEC/D3, suggesting an important role for
β2-integrin-ICAM-1 interactions in PMN adhesion to
CMEC [41].
There is currently no data published regarding the use
of antibody treatment directed against LFA-1, Mac-1, or
β2-integrin in humans for treatment of severe sepsis or
SAE. However, LFA-1- and Mac-1-dependent recruitment
of PMN is not unique to the brain, and studies that
employed murine and rabbit models of sepsis have demon-
strated that antibodies directed against β2-integrin, LFA-1,
and Mac-1 can reduce PMN recruitment and ameliorate
subsequent dysfunction of lung and liver [42-44].
Whether PMN adhesion to the brain microvasculature
in severe sepsis causes brain dysfunction is unclear.
However, PMN are armed with many enzymes involved
in host defense against pathogens, including NADPH
oxidase, myeloperoxidase (MPO), matrix metalloprotein-
ases (MMPs), elastase, and cathepsins [45]. Overwhelming
local recruitment of activated PMN to brain microvascu-
lature could expose CMEC to the deleterious effects of
these enzymes. Both NADPH oxidase and MPO produce
reactive oxygen species (ROS), which directly or indirectly
contribute to the disruption of vascular endothelial cell
intercellular junctions [27,46,47]. ROS production by PMN
isolated from severe sepsis patients, and elevated MPO
concentrations in blood plasma isolated from septic pa-
tients have both been reported [11,48]. MMPs and elastase
can also damage endothelial cell adherens and tight junc-
tions [49,50]. Disruption of the brain microvasculature
may contribute to pathological activation of glial cells
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or neurons and, subsequently, to the development of
SAE [27,28].
At present, there is little pathophysiological data on
SAE, and no studies using human tissues. Animal models
of sepsis are a predominant source of data regarding
potential mechanisms of brain dysfunction in sepsis.
Excessive PMN recruitment, associated with neurological
impairment in the brains of septic mice, has been reported
[13,51]. PMN recruitment was ameliorated by treatment
with antibodies directed against ICAM-1, β2-integrin, and
P-selectin adhesion molecules. Anti-P-selectin antibody
treatment was associated with decreased sickness behav-
iour by septic mice, suggesting a possible role for PMN-
endothelial interactions in brain dysfunction during sepsis.
Our data have several limitations. First, our in vitro culture
model may not fully represent the cerebral microvasculature
in severe sepsis. Brain endothelial cells in vivo are in close
contact with astrocytes, and co-culture of hCMEC/D3 with
astrocytes has been demonstrated to decrease basal protein
expression of ICAM-1 [52]. Therefore, hCMEC/D3 may ex-
press ICAM-1 at a higher basal rate compared to brain
endothelial cells in vivo, which may reduce the window for
up-regulation of ICAM-1 in response to cytokine stimula-
tion. Second, our SSCM does not include all potential medi-
ators that may play a role in leukocyte and/or endothelial
activation in inflammation. The use of SSCM, however,
provides valuable information regarding the acute inflam-
matory state in severe sepsis patients, at a time point
when brain dysfunction most often occurs [3,53].
Conclusions
Our data elucidate the late inflammatory changes in
plasma during the first 24 hours of severe sepsis diagnosis
in ICU patients, and demonstrate inflammation-induced
PMN adhesion to hCMEC/D3, mediated by β2-integrin-
ICAM-1 interaction.
Key messages
 The pathophysiology of sepsis-associated
encephalopathy (SAE) is unknown, but systemic
inflammation may cause dysfunction of the brain
microvasculature.
 We measured inflammatory analytes in plasma
during severe sepsis, and created a severe sepsis
cytokine mixture (SSCM).
 SSCM induced neutrophilic leukocyte (PMN)
adhesion to cultured cerebrovascular endothelial
cells in vitro.
 β2-integrins on PMNs, and ICAM-1 on
cerebrovascular endothelial cells, mediated
increased cellular adhesions.
 PMN adhesion to the brain microvasculature
during severe sepsis may contribute to SAE.
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